Skip to main content

Table 2 Published studies of ovarian suppression with gonadotropin-releasing hormone agonists

From: Cancer and fertility preservation: fertility preservation in breast cancer patients

Reference Year Patients (n) Chemotherapy regimen Pregnancies (%) Births (%) Menses 1 year after therapy (%) Menses at the end of follow-up (%) Study type Outcome
Fox and colleagues [27] 2003 24 AC, AC-T, FAC, AT-CMF 21 8 96 75 Prospective, single-arm Ovarian function preservation
Del Mastro and colleagues [28] 2006 29 100% FEC - - 94 92 Prospective, single-arm Ovarian function preservation
Recchia and colleagues [29] 2002 100 26% CMF, 11% FEC, 54% CMF + epirubicin, 9% HCST 3 2 100   Retrospective, single-arm Ovarian function preservation
Urruticoechea and colleagues [30] 2007 50 78% FEC, 14% AC, 8% AC-T/D 16 16 86 90 Prospective, single-arm Ovarian function preservation
Total   203        
  1. AC, adriamycin (doxorubicin), and cyclophosphamide; AC-T, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); AC-T/D, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; AT-CMF, adriamycin (doxorubicin), taxol (paclitaxel), cyclophosphamide, methotrexate, and 5-fluorouracil; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; HCST, high dose chemotherapy and autologous peripheral blood progenitor cell transplantation.